Product description

» Proprietary strain: Pylopass® is a Lactobacillus reuteri DSMZ 17648, which specifically binds and coaggregates with H. pylori to reduce the bacterial load.
 » Efficiency: Pylopass® decrease the risk of developing gastritis and peptic ulcer disease and can increase the efficacy of Antibiotics treatment. » No side effects: Pylopass® does not alter the microflora of the gut and does not contribute to the antibiotic resistance.

Reduction of H. pylori load in 60% of the subjects in only 2 weeks

Patented Mechanism of Action: Pylopass® is able to recognize surface structures on H. pylori and to form coaggregates. Those Co-aggregates are eliminated from the organism through the gastrointestinal tract. This leads to a reduction of Helicobacter pylori load in the stomach.
Read more

Specifications

Categories Food Supplements / Nutraceuticals
Supplied from Spain
Product Certifications Sustainable Seafood

More products from Tradichem Group

View all our products (14)

Products from other suppliers